Francisco J. Vera-Méndez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francisco J. Vera-Méndez has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Yolanda María Pacheco
Inmunology Service, Laboratory of Immunology, UGC Clinical Laboratories, Institute of Biomedicine of Seville (IBiS)/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain
2 shared publications - Ana Isabel Alvarez-Rios
Servicio de Bioquímica, Hospital Universitario Virgen del Rocío, Sevilla, Spain
1 shared publication - Angel Bulnes-Ramos
Servicio de Inmunología, Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain
1 shared publication - Anna Rull
Hospital Universitari de Tarragona Joan XXIII (HJ23), Tarragona, Spain
1 shared publication - Federico García
Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain
1 shared publication - Félix Gutiérrez
Infectious Diseases Unit, Hospital General Universitario de Elche and Universidad Miguel Hernández de Elche , Alicante
1 shared publication
Latest Publications
- Open Access
- 23 August 2024
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 57 (6) , 854-867
The persistence of low CD4/CD8 ratio in chronic HIV-infection, despite ART suppression and normal CD4 levels, is associated with pre-therapy values of inflammation and thymic function
- 23 August 2024
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 57 (6) , 854-867
Open AccessThe persistence of low CD4/CD8 ratio in chronic HIV-infection, despite ART suppression and normal CD4 levels, is associated with pre-therapy values of inflammation and thymic function
- Open Access
- 16 June 2019
- Published by MDPI AG in Biomolecules
- Vol. 9 (6) , 233
IL7RA rs6897932 Polymorphism Is Associated with Better CD4+ T-Cell Recovery in HIV Infected Patients Starting Combination Antiretroviral Therapy
Interleukin-7 receptor subunit alpha (IL7RA) rs6897932 polymorphism IS related to CD4+ recovery after combination antiretroviral therapy (cART), but no studies so far have analyzed its potential impact in patients with very low CD4+ T-cells count. We aimed to analyze the association between IL7RA rs6897932 polymorphism and CD4+ T-cells count restoration in HIV-infected patients starting combination antiretroviral therapy (cART) with CD4+ T-cells count 20% and was in Hardy–Weinberg equilibrium (p = 0.550). Of 411 patients, 256 carried the CC genotype, while 155 had the CT/TT genotype. The CT/TT genotype was associated with a higher slope of CD4+ T-cells recovery (arithmetic mean ratio; AMR = 1.16; p = 0.016), higher CD4+ T-cells increase (AMR = 1.19; p = 0.004), and higher CD4+ T-cells count at the end of follow-up (AMR = 1.13; p = 0.006). Besides, rs6897932 CT/TT was related to a higher odds of having a value of CD4+ T-cells at the end of follow-up ≥500 CD4+ cells/mm3 (OR = 2.44; p = 0.006). After multiple testing correction (Benjamini–Hochberg), only the increase of ≥ 400 CD4+ cells/mm3 lost statistical significance (p = 0.052). IL7RA rs6897932 CT/TT genotype was related to a better CD4+ T-cells recovery and it could be used to improve the management of HIV-infected patients starting cART with CD4+ T-cells count 3.
- 16 June 2019
- Published by MDPI AG in Biomolecules
- Vol. 9 (6) , 233
Open AccessIL7RA rs6897932 Polymorphism Is Associated with Better CD4+ T-Cell Recovery in HIV Infected Patients Starting Combination Antiretroviral Therapy
Interleukin-7 receptor subunit alpha (IL7RA) rs6897932 polymorphism IS related to CD4+ recovery after combination antiretroviral therapy (cART), but no studies so far have analyzed its potential impact in patients with very low CD4+ T-cells count. We aimed to analyze the association between IL7RA rs6897932 polymorphism and CD4+ T-cells count restoration in HIV-infected patients starting combination antiretroviral therapy (cART) with CD4+ T-cells count 20% and was in Hardy–Weinberg equilibrium (p = 0.550). Of 411 patients, 256 carried the CC genotype, while 155 had the CT/TT genotype. The CT/TT genotype was associated with a higher slope of CD4+ T-cells recovery (arithmetic mean ratio; AMR = 1.16; p = 0.016), higher CD4+ T-cells increase (AMR = 1.19; p = 0.004), and higher CD4+ T-cells count at the end of follow-up (AMR = 1.13; p = 0.006). Besides, rs6897932 CT/TT was related to a higher odds of having a value of CD4+ T-cells at the end of follow-up ≥500 CD4+ cells/mm3 (OR = 2.44; p = 0.006). After multiple testing correction (Benjamini–Hochberg), only the increase of ≥ 400 CD4+ cells/mm3 lost statistical significance (p = 0.052). IL7RA rs6897932 CT/TT genotype was related to a better CD4+ T-cells recovery and it could be used to improve the management of HIV-infected patients starting cART with CD4+ T-cells count 3.